P7C3-A20 treatment one year after TBI in mice repairs the blood–brain barrier, arrests chronic neurodegeneration, and restores cognition

• DOI: 10.1073/pnas.2010430117
• Publication Date: 2020-10-22T00:15:30Z
• Authors: Edwin Vázquez-Rosa; Min-Kyoo Shin; Matasha Dhar; Kalyani Chaubey; Coral J. Cintrón-...; Xinmiao Tang; Xudong Liao; Emiko Miller; Yeojung Koh; Sarah Barker; Kathryn Franke; Danyel R. Crosby; Rachel Schroeder; Josie Emery; Terry C. Yin; Hisashi Fujioka; James D. Reynolds; Matthew M. Harper; Mukesh K. Jain; Andrew A. Pieper
• Keywords: Chronic traumatic encephalopathy

Significance Chronic neurodegeneration, a major cause of the long-term disabilities that afflict survivors traumatic brain injury (TBI), is linked to an increased risk for late-life neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s vascular dementia, and chronic encephalopathy. Here, we report on restoration blood–brain barrier (BBB) structure function by P7C3-A20 when administered 12 mo after TBI. This pharmacotherapy was associated with cessation neurodegeneration recovery normal cognitive function, benefits persisted long treatment cessation. Pharmacologic renewal BBB integrity may thus provide new option patients who have suffered remote TBI, or other neurological conditions deterioration.